The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions

The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhullar, Jasjeet, Natarajan, Karthika, Shukla, Suneet, Mathias, Trevor J., Sadowska, Mariola, Ambudkar, Suresh V., Baer, Maria R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743865/
https://www.ncbi.nlm.nih.gov/pubmed/23967177
http://dx.doi.org/10.1371/journal.pone.0071266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743865/
https://www.ncbi.nlm.nih.gov/pubmed/23967177
http://dx.doi.org/10.1371/journal.pone.0071266

Ejemplares similares